Suggestions
Dan Nardi
Reimagining Cancer Care with Very Talented Colleagues
Dan Nardi is the Chief Executive Officer of Reimagine Care, a leading provider in the healthcare industry.4 He is an innovative and passionate leader with more than 24 years of experience in Healthcare IT.1 Nardi was appointed as the new CEO of Reimagine Care in July 2023.4
Professional Background
Nardi's expertise lies in delivering exceptional patient experiences, which is a core focus of Reimagine Care's mission.2 Under his leadership, the company aims to transform healthcare delivery, particularly in areas such as:
- Digital health solutions
- Employee benefits
- Healthcare quality improvement3
Recent Developments
In early 2024, Nardi announced that Reimagine Care had welcomed Oncology Ventures into their organization, marking a significant expansion for the company.5 This move aligns with Reimagine Care's goal of enhancing cancer care services and improving patient outcomes.
Personal Approach
Nardi is known for his commitment to the human side of healthcare. He has shared personal stories that underscore the importance of their work, including a poignant reminder about a friend diagnosed with cancer.6 This personal connection to the mission of improving cancer care appears to drive his leadership approach at Reimagine Care.
Dan Nardi's LinkedIn username is indeed danjnardi, as confirmed by his professional profile and various posts on the platform.123
Highlights
Reimagine Care is hiring! If you are passionate about improving healthcare delivery, especially cancer care, and you're committed to being excellent in your next career adventure, then please send me a note.
We currently have two open positions, with more to come in the next few months!
- Sr. Partner Experience Manager (think Client Success++)
- Clinical Team Lead (based in Houston, TX)
Financial Toxicity is real, especially for patients battling cancer (see below). Solutions like Reimagine Care are going to be critical for the future reimbursement models in cancer care. A reckoning is coming, we are ready.
We should all be upset when reading the conclusions from this American Society of Clinical Oncology (ASCO) Abstract by Justin Michael Barnes, et. al.
Conclusions: This nationwide population-based analysis suggests that HDHPs are associated with both worse overall survival and cancer survival among cancer survivors but are not associated with survival in adults without a history of cancer. HDHPs may financially disincentivize cancer survivors from utilizing necessary medical care to optimize survivorship thereby compromising mortality and cure. Policy changes to limit the proliferation of these plans may improve cancer outcomes.
